방사선의학 웹진

바로가기  >

Representative BPND parametric map of [18F]FE-PE2I and tyrosine hydroxylase staining section; (a), (b) for normal rat; (c), (d) for Parkinson’s disease-modeling rat​

Abstract

PURPOSE:

This study aimed to assess the striatal [(18)F]FE-PE2I binding and the immunohistochemical stain of tyrosine hydroxylase (TH) in the striatum, and to evaluate the effects of therapeutic drugs on [(18)F]FE-PE2I binding.

METHODS:

Dynamic PET/CT of [(18)F]FE-PE2I was performed in Parkinson's disease (PD) rat models, induced by the unilateral injection of 6-OHDA into the striatum. A simplified reference tissue model method was used to calculate the striatal binding potential (striatal BPND). Each of the four normal rats was pretreated with pramipexole, amantadine, and escitalopram 30min before [(18)F]FE-PE2I injection. The effect of l-DOPA combined with benserazide was assessed in the normal and PD rats.

RESULTS:

The BPND was significantly lower in the lesioned striatum than in the striatum of the normal rats. After the pretreatment with pramipexole, amantadine, and escitalopram, the values of the striatal BPND did not differ from those of the controls. The pretreatment with l-DOPA/benserazide, however, significantly reduced the striatal BPND. The striatal BPND of the PD rats with l-DOPA/benserazide pretreatment was not different from that of the same PD rats with placebo treatment.

CONCLUSION:

[(18)F]FE-PE2I may be used as a radioligand for the in-vivo imaging of the DAT. In the normal rats, [(18)F]FE-PE2I binding is unaffected by pramipexole, amantadine, and escitalopram. l-DOPA/benserazide does not affect the striatal [(18)F]FE-PE2I binding in PD rats.
 

Author information

Bang JI1, Jung IS1, Song YS1, Park HS2, Moon BS1, Lee BC3, Kim SE4.​

1Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Republic of Korea.

2Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Republic of Korea; Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Republic of Korea.

3Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Republic of Korea; Center for Nanomolecular Imaging and Innovative Drug Development, Advanced Institutes of Convergence Technology, 864-1, Iui-dong, Yeongtong-gu, Suwon 443-270, Republic of Korea.

4Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Republic of Korea; Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Republic of Korea; Center for Nanomolecular Imaging and Innovative Drug Development, Advanced Institutes of Convergence Technology, 864-1, Iui-dong, Yeongtong-gu, Suwon 443-270, Republic of Korea. Electronic address: kse@snu.ac.kr.